Merck & Co. Interest Expense 2011-2026 | MRK

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Merck & Co.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-151 M	24 M	-466 M	-1.5 B	806 M	831 M	893 M	772 M	754 M	693 M	672 M	732 M	801 M	714 M	695 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
893 M	-1.5 B	418 M

Quarterly Interest Expense Merck & Co.

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
238 M	7 M	35 M	162 M	-42 M	33 M	-126 M	-172 M	242 M	-	244 M	240 M	243 M	-	196 M	202 M	200 M	-	203 M	209 M	212 M	-	231 M	233 M	209 M	-	190 M	194 M	185 M	-	189 M	193 M	182 M	-	170 M	171 M	172 M	-	165 M	174 M	164 M	-	191 M	188 M	188 M	-	215 M	201 M	184 M	-	178 M	172 M	175 M	-	176 M	170 M	186 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
244 M	-172 M	164 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Alpine Immune Sciences ALPN	98 K	-	-	$ 2.17 B	USA
ASLAN Pharmaceuticals Limited ASLN	442 K	-	-14.27 %	$ 1.7 M	Singapore
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 49.8	-0.86 %	$ 4.48 B	Schweiz
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Celldex Therapeutics CLDX	927 K	$ 31.27	4.37 %	$ 2.08 B	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.67	-6.8 %	$ 30.6 M	Israel
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 2.84	-0.35 %	$ 4.68 M	Israel
Forte Biosciences FBRX	-396 K	$ 17.56	0.92 %	$ 227 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.15	-	$ 655 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA